Cytosorbents (CTSO) Equity Ratio (2010 - 2026)

Cytosorbents has reported Equity Ratio for 17 years, with the latest figure at 0.05 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 81.11% year-over-year to 0.05; the trailing twelve-month figure through Mar 2026 stood at 0.05 (down 81.11% YoY), and the FY2025 full-year result was 0.13, down 43.02% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.05, down from 0.13 in the prior quarter.
• The five-year high for Equity Ratio was 0.67 in Q2 2022, with the low at 0.05 in Q1 2026.
• Historically, Equity Ratio has averaged 0.38 across 5 years, with a median of 0.4 in 2023.
• Annual changes were most pronounced in 2022 — Equity Ratio retreated 11.83% — and 2026, when it tumbled 81.11%.
• Cytosorbents' Equity Ratio stood at 0.56 in 2022, then dropped by 20.75% to 0.44 in 2023, then sank by 47.12% to 0.23 in 2024, then slumped by 43.02% to 0.13 in 2025, then tumbled by 59.52% to 0.05 in 2026.
• The last three Equity Ratio figures came in at 0.05 (Q1 2026), 0.13 (Q4 2025), and 0.2 (Q3 2025), per Business Quant data.